The renin-angiotensin-aldosterone system has long been a target of pharmacological approaches for the control of blood pressure and increasingly for heart failure, myocardial infarction, nephropathy and diabetes. Clinical trials involving the renin-angiotensin-aldosterone axis have traditionally focused on angiotensin-converting enzyme (ACE) inhibitors or angiotensin (Ang) II receptor blockers, thereby laying the emphasis on inhibiting Ang II. It is now acknowledged that aldosterone is also an important culprit in addition to Ang II. Recently, major intervention trials in heart failure have demonstrated the marked cardiovascular beneficial effect of aldosterone antagonism over and above ACE-inhibitor therapy, underscoring the harmful effects of aldosterone in cardiovascular disease. Diabetes is now increasingly recognised as not only a metabolic disorder but a vascular disease as well. Therefore, the prospect arises that aldosterone antagonism may translate in reduced cardiovascular risk in a high-risk disorder like diabetes mellitus. If so, aldosterone antagonists may offer a new therapy in diabetes mellitus for the primary prevention of cardiovascular disease.
Haffner SM, Lehto S., Ronnemaa T., Pyorala K., Laakso M.Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med1998;339:229-34.
2.
UK Prospective Diabetes Study (UKPDS) Group.Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet1998;352:837-53.
3.
UK Prospective Diabetes Study Group.Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. BMJ1998;317:703-13.
4.
Weber KTAldosterone in congestive heart failureN Engl J Med2001;345:1689-97.
5.
Vijayaraghavan K., Deedwania PCThe renin angiotensin system as a therapeutic target to prevent diabetes and its complications. Cardiol Clin2005;23:165-83.
6.
Mizuno Y., Yoshimura M., Yasue H. et al. Aldosterone production is activated in failing ventricle in humans. Circulation2001;103:72-7.
7.
Bonvalet JP, Alfaidy N., Farman N., Lombes M.Aldosterone: intracellular receptors in human heart. Eur Heart J1995 D ;16(suppl N):92-7.
Joffe HV, Adler GKEffect of aldosterone and mineralocorticoid receptor blockade on vascular inflammation. Heart Fail Rev2005;10:31-7.
10.
Connell JM, Davies E.The new biology of aldosterone. J Endocrinol2005;186:1-20.
11.
Wehling M., Spes CH, Win N. et al. Rapid cardiovascular action of aldosterone in man. J Clin Endocrinol Metab1998;83:3517-22.
12.
van Hoeven KH, Factor SMA comparison of the pathological spectrum of hypertensive, diabetic, and hypertensive-diabetic heart disease. Circulation1990;82:848-55.
13.
Dawson A., Morris AD, Struthers ADThe epidemiology of left ventricular hypertrophy in type 2 diabetes mellitus . Diabetologia2005;48:1971-9.
14.
Adeghate E.Molecular and cellular basis of the aetiology and management of diabetic cardiomyopathy: a short review. Mol Cell Biochem2004;261:187-91.
15.
Yamamoto N. , Yasue H., Mizuno Y. et al. Aldosterone is produced from ventricles in patients with essential hypertension. Hypertension2002;39:958-62.
16.
Rocha R., Stier CT, Jr., Kifor I et al. Aldosterone: a mediator of myocardial necrosis and renal arteriopathy . Endocrinology2000;141:3871-8.
17.
MacFadyen RJ , Barr CS, Struthers ADAldosterone blockade reduces vascular collagen turnover, improves heart rate variability and reduces early morning rise in heart rate in heart failure patients. Cardiovasc Res1997;35:30-4.
18.
Pitt B., Zannad F., Remme WJ et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators . N Engl J Med1999; 341:709-17.
19.
Davies J., Gavin A., Band M., Morris A., Struthers A.Spironolactone reduces brachial pulse wave velocity and PIIINP levels in hypertensive diabetic patients. Br J Clin Pharmacol2005 ;59:520-3.
20.
Nishizaka MK , Calhoun DAThe role of aldosterone antagonists in the management of resistant hypertension. Curr Hypertens Rep2005;7: 343-7.
21.
Pitt B., Reichek N., Willenbrock R. et al. Effects of eplerenone, enalapril, and eplerenone/enalapril in patients with essential hypertension and left ventricular hypertrophy: the 4E-left ventricular hypertrophy study. Circulation2003;108:1831-8.
22.
Price DA, De'Oliveira JM, Fisher ND, Williams GH, Hollenberg NKThe state and responsiveness of the renin-angiotensin-aldosterone system in patients with type II diabetes mellitus. Am J Hypertens1999;12:348-55.
23.
Chan JC, Cheung CK, Cockram CS et al. Atrial natriuretic peptide and renin-angiotensin-aldosterone system in non-insulin-dependent diabetes mellitus. J Hum Hypertens1994;8:451-6.
24.
Goodfriend TL, Egan BM, Kelley DEPlasma aldosterone, plasma lipoproteins, obesity and insulin resistance in humans. Prostaglandins Leukot Essent Fatty Acids1999;60:401-05.
25.
Gordon RD, Ziesak MD, Tunny TJ, Stowasser M., Klemm SAEvidence that primary aldosteronism may not be uncommon: 12% incidence among antihypertensive drug trial volunteers. Clin Exp Pharmacol Physiol1993;20:296-8.
26.
Zannad F.EPHESUS: evidence for the cardioprotective effects of selective aldosterone blockade. J Hypertens2004;22:S283. Abstract8A.1.
27.
Farquharson CA, Struthers ADAldosterone induces acute endothelial dysfunction in vivo in humans: evidence for an aldosterone-induced vasculopathy. Clin Sci (Lond)2002;103:425-31.
28.
Suwaidi JA, Hamasaki S., Higano ST, Nishimura RA, Holmes DR, Jr., Lerman A.Long-term follow-up of patients with mild coronary artery disease and endothelial dysfunction. Circulation2000;101:948-54.
29.
Gokce N., Keaney JF, Jr., Hunter LM, Watkins MT, Menzoian JO, Vita JARisk stratification for postoperative cardiovascular events via noninvasive assessment of endothelial function: a prospective study. Circulation2002;105:1567-72.
30.
Hatakeyama H., Miyamori I., Fujita T., Takeda Y., Takeda R., Yamamoto H.Vascular aldosterone. Biosynthesis and a link to Ang II-induced hypertrophy of vascular smooth muscle cells. J Biol Chem1994;269:24316-20.
31.
Duprez D., De Buyzere M., Rietzschel ER, Clement DLAldosterone and vascular damage. Curr Hypertens Rep2000;2:327-34.
32.
Sowers JR, Lester MADiabetes and cardiovascular disease. Diabetes Care1999;22(suppl 3):C14-C20.
33.
Davies JI, Band M., Morris A., Struthers ADSpironolactone impairs endothelial function and heart rate variability in patients with type 2 diabetes. Diabetologia2004;47:1687-94.
34.
Heart Outcomes PreventionEvaluation Study Investigators.Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE sub-study. Lancet2000;355:253-9.
35.
Balkau B., Jouven X., Ducimetiere P., Eschwege E.Diabetes as a risk factor for sudden death. Lancet1999;354:1968-9.
36.
Salles GF, Deccache W., Cardoso CRUsefulness of QT-interval parameters for cardiovascular risk stratification in type 2 diabetic patients with arterial hypertension. J Hum Hypertens2005;19:241-9.
37.
Gerritsen J. , Dekker JM, TenVoorde BJ et al. Impaired autonomic function is associated with increased mortality, especially in subjects with diabetes, hypertension, or a history of cardiovascular disease: the Hoorn Study. Diabetes Care2001;24:1793-8.
38.
Struthers ADTwo new culprits in cardiovascular disease: QT dispersion and aldosterone. J Hum Hypertens1995;9:659-61.
39.
Struthers ADWhy does spironolactone improve mortality over and above an ACE-inhibitor in chronic heart failure?Br J Clin Pharmacol1999;47:479-82.
40.
Khaw KT, Barrett-Connor E.Dietary potassium and stroke-associated mortality. A 12-year prospective population study. N Engl J Med1987;316:235-40.
41.
Juurlink DN , Mamdani MM, Lee DS et al. Rates of hyperkalemia after publication of the Randomized Aldactone Evaluation Study. N Engl J Med2004;351:543-51.
